This article is more than 5 years old. Information may no longer be current.

Akorn completes acquisition of Kilitch Drugs in India

Issue: July/August 2012

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LAKE FOREST, U.S.A. — Akorn announced in a press release that its wholly owned subsidiary, Akorn India Private Limited, has completed and closed its acquisition of certain assets of Kilitch Drugs India Limited and NBZ Pharma Limited.

“We look forward in establishing our global presence with this acquisition as well as expanding our capabilities in becoming a world class sterile injectables manufacturer. We also look forward in working closely with the promoters of [Kilitch Drugs India Limited] to provide a smooth transition in the coming months,” Raj Rai, CEO of Akorn, said in the release.

Akorn is a niche generic pharmaceutical company based in the U.S.

Kilitch Drugs India Limited is a leading contract manufacturer of sterile injectables in India, according to the release. The company has two formulation manufacturing facilities, located in Navi Mumbai and Paonta Sahib.